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Abstract
Background: Over half the cancer deaths in HNPCC families are due to extra-colonic malignancies that include
endometrial and ovarian cancers. The benefits of surveillance for gynecological cancers are not yet proven and
there is no consensus on the optimal surveillance recommendations for women with MMR mutations.
Methods: We performed a systematic review of the literature and evaluated gynecological cancer risk in a series of
631 Polish HNPCC families classified into either Lynch Syndrome (LS, MMR mutations detected) or HNPCC
(fulfillment of the Amsterdam or modified Amsterdam criteria).
Results: Published data clearly indicates no benefit for ovarian cancer screening in contrast to risk reducing surgery.
We confirmed a significantly increased risk of OC in Polish LS families (OR = 4,6, p < 0.001) and an especially high
risk of OC was found for women under 50 years of age: OR = 32,6, p < 0.0001 (95% CI 12,96-81,87). The cumulative
OC risk to 50 year of life was calculated to be 10%. Six out of 19 (32%) early-onset patients from LS families died
from OC within 2 years of diagnosis. We confirmed a significantly increased risk of EC (OR = 26, 95% CI 11,36-58,8;
p < 0,001). The cumulative risk for EC in Polish LS families was calculated to be 67%.
Conclusions: Due to the increased risk of OC and absence of any benefit from gynecological screening reported
in the literature it is recommended that prophylactic oophorectomy for female carriers of MMR mutations after
35 year of age should be considered as a risk reducing option. Annual transvaginal ultrasound supported by
CA125 or HE4 marker testing should be performed after prophylactic surgery in these women.
Due to the high risk of EC it is reasonable to offer, after the age of 35 years, annual clinical gynecologic
examinations with transvaginal ultrasound supported by routine aspiration sampling of the endometrium for
women from either LS or HNPCC families. An alternative option, which could be taken into consideration for
women preferring surgical prevention, is risk reducing total hysterectomy (with bilateral salpingo-oophorectomy)
for carriers after childbearing is complete.
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Background
Lynch syndrome, also referred to as hereditary non-
polyposis colorectal cancer (HNPCC), accounts for
somewhere between 2 and 5% of all CRC [1,2]. It has
been shown that Lynch Syndrome (LS) is a result of
germline mutations in genes involved in DNA mismatch
repair (MMR) MSH2, MLH1, MSH6, and PMS2,
whereas as HNPCC refers to families that adhere to the
Amsterdam criteria or iterations of it. Mutations within
MSH2 and MLH1 are the most frequently observed in
Lynch syndrome [3-6]. More recently, it has been re-
ported that loss of EPCAM is associated with Lynch syn-
drome, by virtue of it changing the epigenetic status of
the promoter region of MSH2 [7]. Mutation carriers are
at high risk of developing colorectal cancer (CRC), and
endometrial cancer (EC) at unusually young ages [8].
Other, extra-colonic tumor types such as ovarian, small
bowel, urinary, biliary tract, gastric, and brain tumors,
have also been associated with HNPCC [9,10]. Due to
the high cumulative risk of CRC colonoscopy is recom-
mended in LS families [11]. This strategy has been docu-
mented to decrease CRC mortality [12]. Over half the
cancer deaths in HNPCC families are due to extra-
colonic malignancies [13]. The benefit of surveillance for
gynecological cancers is not yet proven and there is no
consensus on the optimal surveillance recommendations
for women with MMR mutations. The aim of this study
was to perform a systematic review of the literature and
to evaluate and compare cancer risk in our series of 631
Polish HNPCC families including 279 families with identi-
fied mismatch repair (MMR) gene mutations (referred as
Lynch syndrome (LS) families) in order to suggest optimal
management of ovarian and endometrial cancer for female
MMR mutation carriers and their close relatives.
Material and methods
The relevant literature articles were found after a com-
prehensive search of the Medline (Pubmed) database
from its inception to 17 September 2014 by inputting
“HNPCC”; 4298 publications were identified. A refined
search using combinations of terms: “HNPCC”, “tumor
spectrum”, “ovarian cancer”, “endometrial cancer”,
“screening”, “cancer risk”, “surveillance” and “prophy-
lactics” identified reference used herein.
During 2002-2014 631 HNPCC families studied herein
were classified into either LS or HNPCC at the Inter-
national Hereditary Cancer Center (IHCC) Szczecin,
Poland, due to 1): identification of pathogenic MMR gene
mutations -278 LS families (1176 women, 1507 men); or
2): fulfillment of Amsterdam criteria (144 families, 240
affected individuals and 750 their first-degree relatives)
or HNPCC suspected criteria (at least 2 first degree rel-
atives affected with CRC/EC and at least one of them
diagnosed < 50 yrs- 209 families, 348 affected patients
and 1092 their first-degree relatives) – total 353 families
referred as HNPCC families (with no MMR mutations)
(1285 females, 1145 males). There were 1433 mutation
carriers and 1250 first-degree relatives in LS families: 1371
individuals coming from 142 MLH1 families, 946 individ-
uals from 98 MSH2 families, 347 persons from 36 MSH6
families, 19 individuals from 2 EPCAM families.
Patients originated from different regions of Poland.
All adult LS mutation carriers or first-degree relatives
were included, as well as probands and their adult first
degree-relatives from HNPCC families. We investigated
the tumor spectrum, age of onset of ovarian cancer
(OC) and endometrial cancer (EC), the risk of OC and
EC and survival from OC in these families. Observed
(OF) and expected frequencies (EF) were calculated by
the evaluation of the total number of family members
and affected individuals in different age groups (range of
5 years) in LS and HNPCC families and compared to
age-specific incidence rates in the different age groups
(range 5 years) per 100,000 people. These calculations
were matched by site with the individuals registered in the
Polish general population [14]. Statistical analyses includ-
ing evaluation of expected and observed frequencies and
cumulative risk were performed using Cox regression, chi-
square with Yates correction and T-test analysis.
All participants signed an informed consent document
prior to entering the study. The study was approved
by the institutional review board of the Pomeranian
Medical University.
For 10-year survival analysis a comparison with follow-
up data from a consecutive ovarian cancers was performed.
This group consisted of 608 unselected ovarian cancer pa-
tients (there were no HNPCC- and LS-associated OC in
this series of cases) from the registry of International
Hereditary Cancer Centre in Szczecin, Poland, who were
diagnosed from 1998 to 2006 in cooperating Oncology
Centers in Szczecin, Poznań and Rzeszów. All cases were




Recent analysis of the cancer spectrum in 368 MMR
genes mutation carriers (mainly non-Hispanic white US
citizens) from 176 families confirmed that the two most
common LS cancers were: CRC (58% of all cancers) in
both sexes and EC (14%) followed by ovarian cancer
(OC) as the third most common malignancy (3,5%).
Cancers of the urogenital tract (kidney/uterus/bladder)
constituted 3,1%, stomach/small intestine 2,7%, breast
1,9% and prostate 1.1% of all malignancies in these fam-
ilies [15]. Another study from Europe performed on
2118 German and Dutch MMR gene mutation carriers
revealed a similar tumor spectrum and a high incidence
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of gynecological cancers: CRC 50%, EC 16%, OC 4,4%,
breast 4,4%, urological 3,6%, stomach 1,6% [16]. LS-
associated OC has been reported to exhibit a variety of
histopathological subtypes, mostly invasive, with 22%
presenting with synchronous primary EC [17].
Polish data
Consistent with reports in the literature, a comparison
of the cancer spectrum between 278 LS families and 353
HNPCC families diagnosed at the IHCC confirmed the
high incidence of gynecological cancers in Polish
HNPCC families. There were 21 OCs among 573 tumors
(3,6%) in LS families and 18 OCs among 588 tumors
(3,1%) in the HNPCC families. EC was more prevalent
among LS families (138/573 tumors, 24% of all cancers)
compared to HNPCC families (81/588 tumors, 14% of
all cancers). There were no major differences in the dis-
tribution of other tumors between either the LS or
HNPCC families (Table 1).
In the LS families individual at risk for CRC was 10,7%
(289 CRC among 2683 individuals), for EC 12% (138 cases
among 1176 females), for OC 1,7% (21 patients among
1176 women) and 2,8% for early-onset cases (19 cases
among 661 women before 50). In the HNPCC families in-
dividual at risk for CRC was 14,1% (345 CRC among 2430
individuals), for EC 6,3% (81 cases among 1285 females)
and 1,4% for OC (18 patients among 1285 women).
Risk of ovarian cancer
Literature data
For female LS patients, the lifetime risk of developing OC
is estimated to be somewhere between 3% and 20% with a
standardized incidence ratio (SIR) ranging from 7 to 14
[18-22]. The mean age of OC has been reported to be be-
tween 40 and 47 years of age [16,21,22]. In a recent Danish
study the mean age of OC was reported to be lower in LS
families (41 years) compared to HNPCC families (66 years)
or HNPCC-suspected families (64 years) [23].
Polish data
Statistical analysis of the age of onset of gynecological can-
cers in Polish LS patients reported herein confirmed that
the mean age of OC was significantly lower in these fam-
ilies (43 years, age range 31-52) when compared to the gen-
eral Polish population (54 years, p < 0.0001) and to HNPCC
families (53 years, age range 27-80, p < 0.001).
Table 1 Cancer spectrum in MMR genes mutation positive and negative HNPCC families
Mutation positive Mutation negative
N Mean age % <50 ≥50 N Mean age % <50 ≥50
CRC 289 48,2 50,4 [289/573] 171 118 CRC 345 53,4 58,6 [345/588] 156 189
EC 138 49,8 24,1 [138/573] 69 69 EC 81 51 13,7 [81/588] 41 40
OC 21 42,6 3,66 [21/573] 19 2 OC 18 54,6 3,06 [18/588] 5 13
KI 6 52,2 1,04 [6/573] 3 3 KI 13 57,3 2,21 [13/588] 3 10
BL 5 55,4 0,87 [5/573] 3 2 BL 6 49 1,02 [6/588] 3 3
LC 3 60 0,52 [3/573] 1 2 LC 2 68,5 0,34 [2/588] 0 2
ST 12 52,6 2,09 [12/573] 6 6 ST 9 49,2 1,53 [9/588] 6 3
PC 6 55,2 1,04 [6/573] 2 4 PC 5 56,4 0,85 [5/588] 1 4
Liv 8 47,6 1,39 [8/573] 5 3 Liv 4 60 0,68 [4/588] 1 3
FGT 36 50,7 6,28 [36/573] 17 19 FGT 32 51,4 5,44 [32/588] 14 18
BR 28 52 4,88 [28/573] 9 19 BR 32 51 5,44 [32/588] 16 16
BONES 4 59,2 0,70 [4/573] 1 3 Thr 1 51 0,17 [1/588] 0 1
Gallbladder 1 50 0,17 [1/573] 0 1 SS 1 58 0,17 [1/588] 0 1
CSU 9 51,4 1,57 [9/573] 4 5 CSU 25 52,3 4,25 [25/588] 10 15
SKIN 2 48,5 0,35 [2/573] 1 1 SKIN 2 59,5 0,34 [2/588] 1 1
MM 1 44 0,17 [1/573] 1 0 MM 1 72 0,17 [1/588] 0 1
Lx 1 52 0,17 [1/573] 0 1 OUN 2 35,5 0,34 [2/588] 1 1
OUN 3 42 0,52 [3/573] 2 1 LEUC 6 50,7 1,02 [6/588] 2 4
LEUC 2 63 0,35 [2/573] 0 2 Salivary gland 1 33 0,17 [1/588] 1 0
LYMPH 1 60 0,17 [1/573] 0 1
SS-soft tissue sarcoma, CRC-colorectal cancer, EC-endometrial cancer, BL-bladder cancer, KI- kidney cancer, OC- ovarian cancer, LC- lung cancer, ST- stomach
cancer, PC- prostate cancer, Liv- liver cancer, FGT- female genital tract, BR- breast cancer, Thr- thyroid cancer, CSU- cancer suspected unknow, MM- malignant
melanoma, Lx- larynx cancer, OUN- central nervous system cancer, LEUC- leukemia, LYMPH- lymphoma.
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Statistical analyses of the observed (OF = 21 cases) and
expected frequency (EF = 4,6) of OC in our series of LS
families showed a significantly increased risk of OC (OR =
4,6, 95% CI 2,75-7,78; p < 0.001) in comparison to the gen-
eral population estimates. An especially high risk of OC
was found for women under 50 years of age: OR = 32,6,
95% CI 12,96-81,87; p < 0.0001 (OF = 19 and EF = 0,6).
The cumulative OC risk to 50 year of age was calculated
to be 10% for Polish female LS patients.
Statistical comparison of the OF (n = 18) and EF (n =
5,4) of OC in our series of HNPCC families showed also
significantly, although to a lesser degree than in LS fam-
ilies, increased risk of OC (OR = 3,6, 95%CI 1.34-9.82; p =
0.012). The cumulative OC risk to 85 year of life was cal-
culated to be 6% for Polish females from HNPCC families.
Out of 21 patients affected by OC in the LS families 11
patients harboured MSH2 mutations, 8 females were
MLH1 mutations carriers and 2 carried MSH6 mutations.
Risk of endometrial cancer
Literature data
For female LS patients, the lifetime risk of developing EC
is estimated to be between 30% and 70% with a standard-
ized incidence ratio (SIRs) ranging from 10 to 62
[21,22,24,25]. The mean age of diagnosis for EC has been
reported to be 48, 49 and 54 years in MLH1, MSH2 and
MSH6 mutation carriers respectively [26,27].
Polish data
The mean age of EC diagnosed in our LS families was
50 years of age (range 27-78). The mean age of EC detected
in HNPCC families was 51 years (range 20-75). Statistical
analyses of the observed (OF = 138 cases) and expected fre-
quency (EF = 5,5 cases) of EC in our series of LS families
showed a significantly increased risk of EC when compared
to general population (OR = 26, 95% CI 11,36-58,8; p <
0,001). The cumulative risk for EC in Polish LS families
was calculated to be 67%. Similarly, although to a lesser ex-
tent than in LS families, statistical analyses of the OF (n =
81) and EF (n = 6,5) of EC in our HNPCC families revealed
a significantly increased risk of EC (OR= 14, 95%CI 6,23-
32,98; p < 0,0001). The cumulative risk for EC in Polish
HNPCC families was calculated to be 36%.
Cancer deaths
Literature data
In a recent study of 179 Finnish LS families from 1069 mu-
tation carriers 151 had succumbed - 97 (64%) to cancer.
From these 55,3% cancer deaths were due to extra-colonic,
extra-endometrial cancers; CRC accounted for 36,4% of the
deaths; 8.2% due to EC. Only 7.9% of the patients with
CRC had died from CRC and 5% of those with EC, respect-
ively; 61% of the extra-colonic, extra-endometrial cancer
patients died from their primary disease [13].
Conflicting data regarding prognosis of OC in the
HNPCC exists in the literature. A comparison of 26 OC
from Dutch HNPCC families versus 52 sporadic OC
matched for age, stage and year of diagnosis, derived
from the Dutch population revealed that the survival
rate was not significantly different between patients with
OC-HNPCC and the controls with sporadic OC [28].
There is, however, a second report suggesting that a bet-
ter prognosis of OC in LS, with a 10-year survival of
81%, than in BRCA1/2 mutation carriers or in the gen-
eral population [29].
Polish data
In our series of 21 OC from Polish LS families (3 OC
were excluded from survival calculations due to incom-
plete follow up data) the 10-year survival rate was 61%.
It was significantly higher when compared to 5% of 10-
year survival rate of 600 consecutive patients with OC
(HNPCC patients were excluded) diagnosed at our cen-
ter (Figure 1). This indicates a better prognosis of Lynch
syndrome-associated OC. However, 6 out of 19 (32%) af-
fected patients from LS families died due to OC within
2 years of diagnosis. All but one patient was diagnosed
after their 37th year of age (the youngest woman was 31
at the time of cancer detection). The 10-year survival
rate of OC in our HNPCC subgroup was 21% (Figure 1).
Discussion
Management of ovarian cancer
Majority of LS-associated ovarian cancers show non-
serous histology- an association between endometrioid
and clear cell ovarian carcinomas and hereditary predis-
position due to MMR gene mutation has been reported
[30,31]. There is limited evidence to establish whether
routine screening with serum CA125 levels for the high-
risk population would result in a decrease in mortality
from OC. CA125, mostly associated with serous OCs,
has been reported to to be elevated in around 11% of
the Lynch syndrome or hereditary carcinoma of the
breast/ovary cases; during the premenopausal period ris-
ing values of CA125 were associated with benign pelvic
diseases,such as endometriosis, adenomyosis and myo-
mas [32]. However, current guidelines for gynecological
screening in HNPCC recommend transvaginal ultra-
sound (TVUs) and CA125 testing, every 1-2 years start-
ing at 30-35 years of age [33-35]. Recently it has been
suggested that HE4 marker might be useful for diagnos-
ing OC due to its high specificity, especially in the pre-
menopausal population and combining of HE4 and
CA125 could be considered as an option in the OC
management [36,37].
We found four published studies that included a total
of 585 women screened for the screening method in-
cluded both TVUS and CA125 (applied in three studies)
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or TVUS only (one study). Taken together, 5 OC were
diagnosed in these studies; only 1 OC during surveil-
lance (stage IIIC), the other 4 OC were detected acci-
dentally because of bleeding or surgery performed due
to unrelated reasons and not by surveillance [38-41]. In
all studies no benefit was shown for OC surveillance or
the diagnosis of early stage ovarian cancer OC (Table 2).
A second retrospective study reported on impact of
gynecological screening in 174 MSH2 carriers [42]. Six
of the 54 women in the screened group (TVUS +
CA125/5 years) developed OC and there were 2 deaths
due to OC within the first 2 years after diagnosis. The
same number (six) of 54 matched women (taking into
account age at entry into screening program) in the
non-screened group developed OC, which lead to 3
deaths. In total, 16 OC among 120 unscreened women
occurred, from which 5 deaths had occurred within
2 years. The authors concluded that screening did not
result in any earlier cancer detection and despite screen-
ing, 2 young women died from OC. The authors suggest
that prophylactic surgery be considered in female muta-
tion carriers who have completed childbearing [42] to
reduce their risk of presenting with incurable disease.
Recently an impact of gynecological screening (biennial
TVUS +CA125 in case of abnormal findings/8 years) was
retrospectively evaluated in 236 women (2067 women
years) from Danish LS families. Four cases of OC were di-
agnosed: only one OC in a woman with no symptoms was
detected by surveillance (highly differentiated endome-
trioid adenocarcinoma, stage II B); three other OCs were
diagnosed as interval cancers due to symptoms [23]. Con-
sistently with previous reports, the study showed OC
screening in female LS patients to be futile.
In 2006 risk-reducing bilateral salpingo-oophorectomy
has been shown to be an effective strategy for preventing
OC [43]. Modeling studies of prophylactic surgery ver-
sus gynecologic surveillance for LS women showed that
risk-reducing surgery is associated with the lowest costs
and would increase life-expectancy [44-46].
According to the revised guidelines for the clinical
management of Lynch syndrome prophylactic oophorec-
tomy can be an option to be discussed with mutation
carriers who have completed their families especially
after the age of 40 years [11].
Given the published evidence and our own data show-
ing a high risk of OC for young women from LS families
and the absence of any positive effect of screening we
conclude that it is justified to recommend the option of
prophylactic oophorectomy for female carriers of MMR
mutations after 35 year of age. Since three cases of pri-
mary peritoneal cancers after prophylactic bilateral
salpingo-oophorectomy in HNPCC patients have been
reported [47,48] and previous studies involving women
with BRCA mutations have also reported an incidence
of primary peritoneal cancer after prophylactic bilateral
salpingo-oophorectomy of 0.8 to 1.0 percent. [49,50], an-
nual TVUS and CA125 screening might be considered
as an option of the follow-up after prophylactic surgery
in these women. Conflicting data regarding the progno-
sis of HNPCC-associated OC can be found in the litera-
ture [28,29]. But even if the results of a comparison of
the 10-year survival between our LS-OC and Polish con-
secutive OCs pointed at a better prognosis for OC asso-
ciated with MMR gene mutations, risk-reducing surgery
performed at the age of 35 would save at least 6 young
women from our HNPCC mutation families. Preventive
Figure 1 Survival comparison of the HNPCC associated ovarian cancers and unselected OC from general Polish population.
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Table 2 Literature data regarding gynecological cancer management in Lynch syndrome families
Author Year Patients Methods Outcome/drawback References
Ketabi Z 2014 236 women from LS families/8 years Biennial TVUs/ CA125/ES 1 OC (II B) and 3 interval OCs diagnosed [23]
Gerritzen LH 2009 100 LS carriers or AMS members/2,5 years TVUs/CA125/ES 1 OC diagnosed (III C) [38]
Rijcken FE 2003 41 LS carriers or AMS members/5 years TVUs/CA125/optional ES 1 interval EC detected [39]
Dove-Edwin I 2002 269 AMS females/826 person-years TVUS only 2 cases of EC- neither case detected by surveillance [40]
Renkonen-Sinisalo L 2007 175 LS carriers/759 person-years TVUs/CA125/routine ES 4 OC occured, none detected by surveillance [41]
Stuckless S 2013 174 MSH2 carriers/5 years TVUs/CA125/ES 3 deaths due to OCs both in screened and unscreened females [42]
Schmeler KM 2006 315 LS carriers/10 years Surgery OC: 0/47 cases bilat salpino-oophorect. (0%) vs 12/223 no surgery
(5.5%) EC: 0/61 hysterectomy (0%) vs 69/210 no surgery (33%) Surgical
complication rate 1.6 percent, no data regarding overall survival
[43]
Manchandra R 2012 41 women from LS families/8 years TVUs/routine ES TVU alone missed 1 EC and 1 premalignant lesion [56]
TUV – transvaginal ultrasound.













oophorectomy was reported to be associated with an
80% reduction in the risk of ovarian, fallopian tube, or
peritoneal cancer in BRCA1 or BRCA2 carriers and a
77% reduction in all-cause mortality [51], even if it has
been observed that BRCA1/2-associated OC patients
have a longer progression-free survival and overall sur-
vival compared with women with sporadic OC [52,53].
Approximately one-third of Polish LS-associated OC pa-
tients died within two years after diagnosis, most prob-
ably due to different chemosensitivity of their tumors.
Ovarian cancers are usually treated by platinium-based
therapy. Contrary to serous sporadic OC and BRCA1-
related OC, decreased susceptibility to cisplatin therapy
has been suggested to be characteristic feature for Lynch
syndrome-associated OC [54].
Management of endometrial cancer
We found six reported studies that included a total of
1518 women screened for EC [23,38-41,55]. In the stud-
ies that used TVUS as the only screening method, inter-
val ECs were diagnosed [40,55]. In the studies in which
protocols also included endometrial biopsies the detec-
tion of premalignant lesions and EC was significantly
improved. A comparison of the results of routine endo-
metrial biopsy [38,41] and optional biopsy (performed in
cases with abnormalities - bleeding, irregular endomet-
rium, endometrium thickness >4 mm [23,39] or >5 mm
[38] in postmenopausal women) revealed better effi-
ciency in disease detection in the protocols that included
routine biopsies where the EC detection rate exceeded
70% in comparison to a 50% detection rate when op-
tional sampling was performed.
Additionally, in another recent report two endometrial
carcinomas and two premalignant lesions were identified
in 41 women who underwent 69 annual visits with
standard TVU and outpatient hysteroscopy with endo-
metrial sampling. Screening with TVU alone would have
missed one endometrial carcinoma and one premalig-
nant lesion in that study [56].
Unlike others, Helder-Woolderink et al. [57] reported
a lack of additional value in endometrial sampling for
EC detection. 75 LS patients or their first-degree rela-
tives at 50% risk of carrying the MMR mutation were
analysed in this study, including women who underwent
annual screening program based upon TVUS alone and
women screened by both TVUS and routine endometrial
sampling. No interval EC was diagnosed.
A large meta-analysis of sporadic endometrial cancers
advocated Pipelle endometrial sampling as an equally ef-
fective, if not superior, method compared with transvagi-
nal ultrasound for detecting endometrial cancer in both
pre- and postmenopausal women [58]. A recent pro-
spective study showed that conducting endometrial sam-
pling at the time of colonoscopy (for colorectal cancer
risk assessment) is a patient-centered option that is feas-
ible, acceptable, and may improve adherence to LS screen-
ing recommendations [59].
Comparison of the results of the screening performed
in 236 LS patients revealed that EC surveillance should
only be targeted to this group of women [23].
Until now no prospective study has evaluated the im-
pact of the EC screening on the survival of LS or
HNPCC patients and the efficiency of screening for EC
that generally presents with symptoms at an early stage
is not clear. However, given the high risk of EC in female
LS patients, according to the revised guidelines for the
clinical management of LS, transvaginal ultrasound and
aspiration biopsy (starting from the age of 35-40 years)
should be offered as an appropriate risk reducing strat-
egy [11]. Recently a retrospective study was published
on the impact of gynecological screening in 174 MSH2
female carriers [42]. Nine of 54 women in the screened
group (TVUS + endometrial sampling/5 years) developed
EC, with no deaths due to this malignancy. Twenty of 54
matched women (taking into account age at entry into
screening program) in the non-screened group devel-
oped EC, which resulted in 3 deaths. In total, 44 ECs
among 120 unscreened women occurred, leading to 11
deaths [42]. The authors argued that risk-reducing hys-
terectomy and bilateral salpingo-oophorectomy after
childbearing is complete is the most effective risk reduc-
tion strategy.
Modeling studies have shown that prophylactic hyster-
ectomy and bilateral salpingo-oophorectomy can increase
life expectancy and can also be a cost-effective strategy
[44-46]. Total hysterectomy was shown to significantly re-
duce the risk of EC in women with Lynch syndrome [43].
However, given better outcomes than those observed for
OC, the screening efficiency in detecting EC and high sur-
vival rates for this cancer [60] it remains unclear whether
surgical prevention of EC in MMR carriers would signifi-
cantly impact on morbidity and mortality.
In conclusion, our present knowledge on Lynch syn-
drome indicates that special prevention and treatment op-
tions should be applied to patients with LS. Due to the
increased risk of OC, conflicting data regarding the prog-
nosis of this disease in HNPCC and lack of any benefit
from gynecological screening, it is recommended that
prophylactic oophorectomy for female carriers of MMR
mutations after 35 year of age should be considered as a
risk reducing option. Annual transvaginal ultrasound
(TVUS) supported by CA125 or HE4 marker might be
considered as an option of the follow-up after prophylactic
surgery in these women.
Due to the high risk of EC it is reasonable to offer, after
the age of 35 years, annual clinical gynecologic examina-
tions with transvaginal ultrasound (TVUS) supported by
routine aspiration sampling of the endometrium to women
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from either LS or HNPCC families. Another option that
could be taken into consideration for women preferring
surgical prevention as a risk reducing alternative is total
hysterectomy (with bilateral salpingo-oophorectomy) for
carriers after childbearing is complete.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Conception and design: TD, JL. Acquiring, analysis and interpretation of data:
TD, TG, JG, TH, TB, GK, CC, BG, PSF, DD; drafting the manuscript: KPS, TG;
critical revision for important intelectual content: RJS, JL; final approval:
TD, RJS. All authors read and approved the final manuscript.
Author details
1Department o f Genetics and Pathology, International Hereditary Cancer
Center, Pomeranian Medical University, Szczecin, Poland. 2Discipline of
Medical Genetics, Faculty of Health, University of Newcastle and Hunter
Medical Research Institute, Newcastle, NSW, Australia.
Received: 1 October 2014 Accepted: 5 January 2015
References
1. Aaltonen L, Johns L, Järvinen H, Mecklin JP, Houlston R. Explaining the
familial colorectal cancer risk associated with mismatch repair (MMR)-
deficient and MMR-stable tumors. Clin Cancer Res. 2007;13:356–61.
2. Aarnio M. Clinicopathological features and management of cancers in lynch
syndrome. Patholog Res Int. 2012;12:1–6.
3. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, et al. The
human mutator gene homolog MSH2 and its association with hereditary
nonpolyposis colon cancer. Cell. 1993;75:1027–38.
4. Leach FS, Nicolaides NC, Papadopoulos N, Liu B, Jen J, Parsons R, et al.
Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer.
Cell. 1993;75:1215–25.
5. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, et al.
Mutations of two PMS homologues in hereditary nonpolyposis colon
cancer. Nature. 1994;371:75–80.
6. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA,
et al. Mutation of a mutL homolog in hereditary colon cancer. Science.
1994;263:1625–9.
7. Tutlewska K, Lubinski J, Kurzawski G. Germline deletions in the EPCAM gene
as a cause of Lynch syndrome - literature review. Hered Cancer Clin Pract.
2013;11:9.
8. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med.
2003;348:919–32.
9. Watson P, Vasen HF, Mecklin JP, Bernstein I, Aarnio M, Järvinen HJ, et al. The
risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J
Cancer. 2008;123:444–9.
10. Lin-Hurtubise KM, Yheulon CG, Gagliano Jr RA, Lynch HT. Excess of
extracolonic non-endometrial multiple primary cancers in MSH2 germline
mutation carriers over MLH1. J Surg Oncol. 2013;108:433–7.
11. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, et al. Revised
guidelines for the clinical management of Lynch syndrome (HNPCC):
recommendations by a group of European experts. Gut. 2013;62:812–23.
12. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki
P, et al. Controlled 15-year trial on screening for colorectal cancer in families
with hereditary nonpolyposis colorectal cancer. Gastroenterology.
2000;118:829–34.
13. Pylvänäinen K, Lehtinen T, Kellokumpu I, Järvinen H, Mecklin JP. Causes of
death of mutation carriers in Finnish Lynch syndrome families. Fam Cancer.
2012;11:467–71.
14. Wojciechowska U, Didkowska J, Zatoński W. Cancer in Poland in 2010.
Warsaw: The Maria-Skłodowska-Curie Memorial Cancer Center, Department
of Epidemiology and cancer Prevention, Polish National Cancer
Registry; 2012.
15. Pande M, Wei C, Chen J, Amos CI, Lynch PM, Lu KH, et al. Cancer spectrum
in DNA mismatch repair gene mutation carriers: results from a hospital
based Lynch syndrome registry. Fam Cancer. 2012;11:441–7.
16. Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, et al.
Risks of less common cancers in proven mutation carriers with lynch
syndrome. J Clin Oncol. 2012;30:4409–15.
17. Watson P, Bützow R, Lynch HT, Mecklin JP, Järvinen HJ, Vasen HF, et al. The
clinical features of ovarian cancer in hereditary nonpolyposis colorectal
cancer. Gynecol Oncol. 2001;82:223–8.
18. Hampel H, Stephens JA, Pukkala E, Sankila R, Aaltonen LA, Mecklin JP, et al.
Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age
of onset. Gastroenterology. 2005;129:415–21.
19. Barrow E, Robinson L, Alduaij W, Shenton A, Clancy T, Lalloo F, et al.
Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a
report of 121 families with proven mutations. Clin Genet. 2009;75:141–9.
20. Stuckless S, Parfrey PS, Woods MO, Cox J, Fitzgerald GW, Green JS, et al. The
phenotypic expression of three MSH2 mutations in large Newfoundland
families with Lynch syndrome. Fam Cancer. 2007;6:1–12.
21. Aarnio M, Mecklin JP, Aaltonen LA, Nyström-Lahti M, Järvinen HJ. Life-time
risk of different cancers in hereditary non-polyposis colorectal cancer
(HNPCC) syndrome. Int J Cancer. 1995;64:430–3.
22. Quehenberger F, Vasen HF, van Houwelingen HC. Risk of colorectal and
endometrial cancer for carriers of mutations of the hMLH1 and hMSH2
gene: correction for ascertainment. J Med Genet. 2005;42:491–6.
23. Ketabi Z, Gerdes AM, Mosgaard B, Ladelund S, Bernstein I. The results of
gynecologic surveillance in families with hereditary nonpolyposis colorectal
cancer. Gynecol Oncol. 2014;133:526–30.
24. Auranen A, Joutsiniemi T. A systematic review of gynecological cancer
surveillance in women belonging to hereditary nonpolyposis colorectal cancer
(Lynch syndrome) families. Acta Obstet Gynecol Scand. 2011;90:437–44.
25. Barrow PJ, Ingham S, O’Hara C, Green K, McIntyre I, Lalloo F, et al. The
spectrum of urological malignancy in Lynch syndrome. Fam Cancer.
2013;12:57–63.
26. Rodriguez-Bigas MA, Möeslein G. Surgical treatment of hereditary
nonpolyposis colorectal cancer (HNPCC, Lynch syndrome). Fam Cancer.
2013;12:295–300.
27. Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger
F, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to
MSH6 mutations: impact on counseling and surveillance. Gastroenterology.
2004;127:17–25.
28. Crijnen TE, Janssen-Heijnen ML, Gelderblom H, Morreau J, Nooij MA, Kenter
GG, et al. Survival of patients with ovarian cancer due to a mismatch repair
defect. Fam Cancer. 2005;4:301–5.
29. Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, et al.
Survival in women with MMR mutations and ovarian cancer: a multicentre
study in Lynch syndrome kindreds. J Med Genet. 2010;47:99–102.
30. Chui MH, Ryan P, Radigan J, Ferguson SE, Pollett A, Aronson M, et al. The
histomorphology of Lynch syndrome-associated ovarian carcinomas: toward
a subtype-specific screening strategy. Am J Surg Pathol. 2014;38:1173–81.
31. Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Järvinen HJ, Mecklin JP,
et al. Distinct molecular profiles in Lynch syndrome-associated and sporadic
ovarian carcinomas. Int J Cancer. 2013;133:2596–608.
32. Karlan BY, Platt LD. Ovarian cancer screening. The role of ultrasound in early
detection. Cancer. 1995;76:2011–5.
33. Lindor NM, Petersen GM, Hadley DW, Kinney AY, Miesfeldt S, Lu KH, et al.
Recommendations for the care of individuals with an inherited predisposition
to Lynch syndrome: a systematic review. JAMA. 2006;296:1507–17.
34. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/
HNPCC. Clin Transl Oncol. 2008;10:313–7.
35. Meyer LA, Broaddus RR, Lu KH. Endometrial cancer and Lynch syndrome:
clinical and pathologic considerations. Cancer Control. 2009;16:14–22.
36. Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum
HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis.
Tumour Biol. 2014;35:6127–38.
37. Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S,
Ganje MB, et al. HE4 combined with CA125: favorable screening tool for
ovarian cancer. Med Oncol. 2014;31:808.
38. Gerritzen LH, Hoogerbrugge N, Oei AL, Nagengast FM, van Ham MA,
Massuger LF, et al. Improvement of endometrial biopsy over transvaginal
ultrasound alone for endometrial surveillance in women with Lynch
syndrome. Fam Cancer. 2009;8:391–7.
39. Rijcken FE, Mourits MJ, Kleibeuker JH, Hollema H, van der Zee AG.
Gynecologic screening in hereditary nonpolyposis colorectal cancer.
Gynecol Oncol. 2003;91:74–80.
Dębniak et al. Hereditary Cancer in Clinical Practice  (2015 13:3 Page 8 of 9
40. Dove-Edwin I, Boks D, Goff S, Kenter GG, Carpenter R, Vasen HF, et al. The
outcome of endometrial carcinoma surveillance by ultrasound scan in
women at risk of hereditary nonpolyposis colorectal carcinoma and familial
colorectal carcinoma. Cancer. 2002;94:1708–12.
41. Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP,
Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis
colorectal cancer syndrome. Int J Cancer. 2007;120:821–4.
42. Stuckless S, Green J, Dawson L, Barrett B, Woods MO, Dicks E, et al. Impact
of gynecological screening in Lynch syndrome carriers with an MSH2
mutation. Clin Genet. 2013;83:359–64.
43. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al.
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch
syndrome. N Engl J Med. 2006;354:261–9.
44. Yang KY, Caughey AB, Little SE, Cheung MK, Chen LM. A cost-effectiveness
analysis of prophylactic surgery versus gynecologic surveillance for women
from hereditary non-polyposis colorectal cancer (HNPCC) Families.
Fam Cancer. 2011;10:535–43.
45. Kwon JS, Sun CC, Peterson SK, White KG, Daniels MS, Boyd-Rogers SG, et al.
Cost-effectiveness analysis of prevention strategies for gynecologic cancers
in Lynch syndrome. Cancer. 2008;113:326–35.
46. Chen LM, Yang KY, Little SE, Cheung MK, Caughey AB. Gynecologic cancer
prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer
families. Obstet Gynecol. 2007;110:18–25.
47. Schmeler KM, Daniels MS, Soliman PT, Broaddus RR, Deavers MT, Vu TM,
et al. Primary peritoneal cancer after bilateral salpingo-oophorectomy in
two patients with Lynch syndrome. Obstet Gynecol. 2010;115:432–4.
48. Ghezzi F, Uccella S, Cromi A, Bogani G, Donadello N, Riva C. Primary
peritoneal cancer in Lynch syndrome: a clinical-pathologic report of a case
and analysis of the literature. Int J Gynecol Pathol. 2013;32:163–6.
49. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van’t Veer L, Garber JE,
et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
N Engel J Med. 2002;346:1616–22.
50. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al.
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2
mutation. N Engl J Med. 2002;346:1609–15.
51. Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, et al. Impact of
oophorectomy on cancer incidence and mortality in women with a BRCA1
or BRCA2 mutation. J Clin Oncol. 2014;32:1547–53.
52. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S.
Effect of BRCA1/2 mutations on long-term survival of patients with invasive
ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol.
2008;26:20–5.
53. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, et al.
“BRCAness” syndrome in ovarian cancer: a case-control study describing the
clinical features and outcome of patients with epithelial ovarian cancer
associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26:5530–6.
54. Marcelis CL, van der Putten HW, Tops C, Lutgens LC, Moog U.
Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation?
Fam Cancer. 2001;1:107–9.
55. Lécuru F, Le Frère Belda MA, Bats AS, Tulpin L, Metzger U, Olschwang S,
et al. Performance of office hysteroscopy and endometrial biopsy for
detecting endometrial disease in women at risk of human non-polyposis
colon cancer: a prospective study. Int J Gynecol Cancer. 2008;18:1326–31.
56. Manchanda R, Saridogan E, Abdelraheim A, Johnson M, Rosenthal AN,
Benjamin E, et al. Annual outpatient hysteroscopy and endometrial
sampling (OHES) in HNPCC/Lynch syndrome (LS). Arch Gynecol Obstet.
2012;286:1555–62.
57. Helder-Woolderink JM, De Bock GH, Sijmons RH, Hollema H, Mourits MJ.
The additional value of endometrial sampling in the early detection of
endometrial cancer in women with Lynch syndrome. Gynecol Oncol.
2013;131:304–8.
58. Dijkhuizen FP, Mol BW, Brölmann HA, Heintz AP. The accuracy of
endometrial sampling in the diagnosis of patients with endometrial
carcinoma and hyperplasia: a meta-analysis. Cancer. 2000;89:1765–72.
59. Huang M, Sun C, Boyd-Rogers S, Burzawa J, Milbourne A, Keeler E, et al.
Prospective study of combined colon and endometrial cancer screening in
women with lynch syndrome: a patient-centered approach. J Oncol Pract.
2011;7:43–7.
60. Lu KH, Daniels M. Endometrial and ovarian cancer in women with Lynch
syndrome: update in screening and prevention. Fam Cancer. 2013;12:273–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Dębniak et al. Hereditary Cancer in Clinical Practice  (2015 13:3 Page 9 of 9
